肝癌组织IFITM3蛋白表达水平及其与肝细胞癌患者手术切除术后肝内肿瘤复发的相关性分析*

doi:10.3969/j.issn.1672-5069.2019.01.031

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (1): 117-120.doi: 10.3969/j.issn.1672-5069.2019.01.031

肝癌组织IFITM3蛋白表达水平及其与肝细胞癌患者手术切除术后肝内肿瘤复发的相关性分析^*

代晓楠, 吕金燕, 翁文采, 郑丽丽

116021 辽宁省大连市大连大学附属新华医院介入治疗科（代晓楠,翁文采）; 消化内科（郑丽丽）; 大连大学附属中山医院肿瘤内科(吕金燕）

收稿日期:2017-11-28 出版日期:2019-01-10 发布日期:2019-01-16
通讯作者: 翁文采,E-mail:wencaidl@163.com
作者简介:代晓楠,女,39岁,主治医师。研究方向：肝癌、直肠癌相关疾病治疗。E-mail:25649037@qq.com
基金资助:
*辽宁省自然科学基金资助项目（编号：2012010311-301）

Expression of IFITM3 in hepatocellular carcinoma and its correlation with intrahepatic tumor recurence after hepatectomy

Dai Xiaonan, Lyu Jinyan, Weng Wencai, et al.

Department of Interventional Therapy,Xinhua Hospital Affiliated to Dalian University,Dalian 116021,Liaoning Province,China

Received:2017-11-28 Online:2019-01-10 Published:2019-01-16

摘要/Abstract

摘要： 目的探讨肝细胞癌（HCC）组织干扰素诱导跨膜蛋白 3（IFITM3）表达水平及其临床意义。方法在我院接受根治性手术切除治疗的43例HCC患者,术中取癌组织和癌旁肝组织,分别采用Western blot法和免疫组化法检测组织IFITM3蛋白表达情况,比较肝内肿瘤复发与未复发患者癌组织IFITM3表达的差异。结果经Western blot法检测肝癌组织IFITM3表达水平为（1.2386±0.1901）,显著高于癌旁组织的（0.9496±0.0995,t=8.832,P=0.000）;免疫组化法检测显示肝癌组织IFITM3蛋白阳性率为72.1%（31/43）,明显高于癌旁组织的14.0%（6/43,x²=29.647,P=0.000）;中分化肝癌组织IFITM3蛋白阳性率为90.9%（10/11）,低分化肝癌组织为95.2%（20/21）,均明显高于高分化组的9.1%（1/11）（x²=14.727, P=0.000;x²=23.748,P=0.000）;术后复发组癌组织IFITM3蛋白阳性率为81.0%（17/21）,未复发组为22.7%（5/22）,两者比较差异具有统计学意义（x²=14.578,P=0.000）。结论 HCC组织IFITM3蛋白呈高表达,且肝癌分化越差,IFITM3表达也越强,并可能与术后肿瘤复发有关。

关键词: 肝细胞癌, 干扰素诱导跨膜蛋白 3, 肿瘤复发, 免疫组化

Abstract: Objective To investigate the expression of interferon-induced transmembrane protein （IFITM3） in hepatocellular carcinoma（HCC） and its correlation with intrahepatic tumor recurence after hepatectomy. Methods A total of 43 patients with HCC were recruited in our hospital,and all of them received hepatectomy. The specimens of cancer and its adjacent liver tissues were taken,and the expression of IFITM3 was detected by Western blot and by immunohistochemistry. All the patients were followed-up for 1 years. Results The expression of IFITM3 protein in HCC tissues was （1.2386±0.1901）,significantly stronger than （0.9496±0.0995） in the adjacent tissues （t=8.832,P=0.000）；the results of immunohistochemical staining showed that the brownish yellow granular IFITM3 protein located in the cytoplasm of liver cancer tissues and adjacent tissues,and the positive rate of IFITM3 protein in hepatocellular carcinoma was 72.1%（31/43）,significantly higher than 14.0%（6/43） in adjacent tissues（x²=29.647,P=0.000）；the positive rate of IFITM protein in low and medium differentiated HCC tissues were 95.2%（20/21） and 90.9%（10/11）,significantly higher than 9.1%（1/11） in high differentiated group（x²=14.727,P=0.000；x²=23.748,P=0.000）；the positive rate of IFITM3 protein in patients with recurrent intrahepatic tumor was 81.0% （17/21）,much higher than 22.7% （5/22） in without tumor recurrence（x²=14.578,P=0.000）. Conclusion IFITM3 protein is highly expressed in HCC tissues,and the worse the differentiation of HCC,the stronger the degree of expression,which might closely be related to the recurrence of HCC after hepatectomy.

Key words: Hepatoma, Interferon-induced transmembrane protein, Tumor recurrence, Immunohistochemistry

代晓楠, 吕金燕, 翁文采, 郑丽丽. 肝癌组织IFITM3蛋白表达水平及其与肝细胞癌患者手术切除术后肝内肿瘤复发的相关性分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 117-120.

Dai Xiaonan, Lyu Jinyan, Weng Wencai, et al.. Expression of IFITM3 in hepatocellular carcinoma and its correlation with intrahepatic tumor recurence after hepatectomy[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 117-120.

参考文献

[1] 毛一雷,徐海峰. 原发性肝细胞癌的早期诊断. 中华内科杂志,2014,53(7):508-510.
[2] 谭凯,杜锡林,杨涛,等. 手术切除、肝动脉化疗栓塞、微波固化联合门静脉化疗对肝细胞癌术后复发的疗效分析. 中华肝胆外科杂志,2014,20(4):253-257.
[3] 李果,吴黎雳,宦宏波,等. 肝细胞癌肝外转移对患者生存预后的影响. 中华解剖与临床杂志,2014,19(4):307-309.
[4] Hu J,Wang S,Zhao Y,et al.Mechanism and biological significance of the overexpression of IFITM3 in gastric cancer. Oncol Rep,2014,32(6):2648-2656.
[5] Jia Y,Zhang M,Jiang W,et al.Overexpression of IFITM3 predicts the high risk of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy. Peerj,2015;3:e1355.
[6] Nakajima A,Ibi D,Nagai T,et al.Induction of interferon-induced transmembrane protein 3 gene expression by lipopolysaccharide in astrocytes. Eur J Pharmacol,2014,745:166-175.
[7] Mcmichael TM,Zhang L,Chemudupati M,et al.The palmitoyltransferase ZDHHC20 enhances interferon-induced transmembrane protein 3(IFITM3) palmitoylation and antiviral activity. J Biol Chem,2017,292(52):21517-21526.
[8] 贾户亮,钦伦秀. 肝细胞癌术后复发的预测与预防策略. 中华肝脏病杂志,2016,24(5):330-334.
[9] 王浩,周岩冰,牛兆建,等. 早期胃癌预后及复发转移因素分析. 中华普通外科杂志,2015,30(8):639-642.
[10] 丛文铭. 肝癌复发转移的分子机制与病理学评估策略. 中华肝脏病杂志,2016,24(5):324-326.
[11] Mills TC,Rautanen A,Elliott KS,et al.IFITM3 and susceptibility to respiratory viral infections in the community. J Infet Dis,2014,209:1028-1031.
[12] Yu M,Qi W,Huang Z,et al.Expression profile and histological distribution of IFITM1 and IFITM3 during H9N2 avian influenza virus infection in BALB/c mice. Med Microbiol Immunol,2015,204(4):505-514.
[13] Bailey CC,Kondur HR,Huang I,et al.Interferon-induced transmembrane protein 3 is a type II transmembrane protein. J Biol Chem,2013,288(45):32184-32193.
[14] Xu J,Qian P,Wu Q,et al.Swine interferon-induced transmembrane protein,sIFITM3,inhibits foot-and-mouth disease virus infection in vitro and in vivo. Antiviral Res,2014,109(9):22-29.
[15] Narayana SK,Helbig KJ,Mccartney EM,et al.The interferon-induced transmembrane proteins,IFITM1,IFITM2,and IFITM3 inhibit hepatitis C virus entry. J Biol Chem,2015,290(43):25946-25959.
[16] Eltanani MK,Jin D,Campbell FC,et al.Interferon-induced transmembrane 3 binds osteopontin in vitro:expressed in vivo IFITM3 reduced OPN expression. Oncogene,2010,29(5):752-62.
[17] 万佳,张硕,李阿茜,等.干扰素诱导的跨膜蛋白IFITM1/2/3对SFTS病毒感染的影响. 中华实验和临床病毒学杂志,2016,30(3):279-282.
[18] Li D,Peng Z,Tang H,et al.KLF4-mediated negative regulation of IFITM3 expression plays a critical role in colon cancer pathogenesis. Clin Cancer Res,2011,17(11):3558-3568.
[19] Zhao B,Wang H,Zong G, et al.The role of IFITM3 in the growth and migration of human glioma cells. BMC Neurol,2013,13(1):210.
[20] Zhang D,Wang H,He H,et al.Interferon induced transmembrane protein 3 regulates the growth and invasion of human lung adenocarcinoma. Thoracic Cancer,2017,8(4):337-343.

肝癌组织IFITM3蛋白表达水平及其与肝细胞癌患者手术切除术后肝内肿瘤复发的相关性分析^*

Expression of IFITM3 in hepatocellular carcinoma and its correlation with intrahepatic tumor recurence after hepatectomy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[2]	朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723.
[3]	王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727.
[4]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[5]	杨富存, 尚怀学, 盖永浩. 钆塞酸二钠增强磁共振扫描诊断肝脏局灶性病变研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 577-580.
[6]	彭新健, 肖玉辉, 许斯鼎, 石荣跃, 王耀政, 王瑜琳. 放射性肝损伤患者肝脏磁共振扩散加权成像表现特征分析[J]. 实用肝脏病杂志, 2019, 22(3): 373-376.
[7]	乔志忠. 超声造影定量分析鉴别肝脏局灶性结节性增生与原发性肝癌初步探讨[J]. 实用肝脏病杂志, 2019, 22(3): 421-424.
[8]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[9]	王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251.
[10]	幸奠奎,程婧. ¹⁸F-FDG PET/CT检查指标预测肝细胞癌微血管侵犯临床价值研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 252-254.
[11]	王秀清,马艳君,詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析 ^*[J]. 实用肝脏病杂志, 2019, 22(2): 260-263.
[12]	张小舟,帅领,王庆大,杨楠. 接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 268-271.
[13]	王朝霞,关珂,付三仙,王慧杰. 肠内肠外联合营养支持治疗肝细胞癌患者围术期临床研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 272-275.
[14]	赵西太综述,聂青和审校. 循环microRNA早期诊断肝细胞癌研究现状及方法学探讨[J]. 实用肝脏病杂志, 2019, 22(2): 297-300.
[15]	范建高. 2018年《实用肝脏病杂志》精彩回顾[J]. 实用肝脏病杂志, 2019, 22(1): 1-3.